Vaccinex, announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer’s disease at the Alzheimer’s Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session. Vaccinex scientists discovered and published that SEMA4D, a molecule that binds to high affinity plexin-B1 receptors predominantly expressed on astrocytes in the brain, is highly upregulated on stressed or damaged neurons during progression of Alzheimer’s Disease. Key outcomes of the SIGNAL-AD study will include safety and tolerability and the impact of pepinemab treatment on brain metabolic activity determined by FDG-PET and astrocyte reactivity as detected by plasma levels of glial fibrillary acidic protein, a molecule known to be released into blood by reactive astrocytes and believed to be a key biomarker of disease progression
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCNX:
- Vaccinex files to sell 490,509 shares of common stock for holders
- Vaccinex Completes Key Study Phase for Alzheimer’s Drug
- Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
- Vaccinex reports completion of last patient visit in SIGNAL-AD Phase 1b/2 study
- Biotech Alert: Searches spiking for these stocks today